Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 14
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment

  • Rubio Pérez, Carlota
  • Planas Rigol, Ester
  • Trincado, Juan L.
  • Bonfill Teixidor, Ester
  • Arias Piñeiro, Alexandra
  • Marchese, Domenica
  • Iurlaro, Raffaella
  • Martínez Ricarte, Francisco Ramón
  • Escudero Monreal, Laura
  • Cordero Asanza, Esteban Xavier
  • Cicuendez López Ocaña, Marta
  • Nuciforo, Paolo Giovanni
  • Sahuquillo Barris, Joan
  • Tabernero Caturla, Josep
  • Seoane Suarez, Joan
  • Serna, Garazi
Microambient del càncer; Immunologia tumoral, Microambiente del cáncer; Inmunología tumoral, Cancer microenvironment; Tumour immunology, Brain metastases are the most common tumor of the brain with a dismal prognosis. A fraction of patients with brain metastasis benefit from treatment with immune checkpoint inhibitors (ICI) and the degree and phenotype of the immune cell infiltration has been used to predict response to ICI. However, the anatomical location of brain lesions limits access to tumor material to characterize the immune phenotype. Here, we characterize immune cells present in brain lesions and matched cerebrospinal fluid (CSF) using single-cell RNA sequencing combined with T cell receptor genotyping. Tumor immune infiltration and specifically CD8+ T cell infiltration can be discerned through the analysis of the CSF. Consistently, identical T cell receptor clonotypes are detected in brain lesions and CSF, confirming cell exchange between these compartments. The analysis of immune cells of the CSF can provide a non-invasive alternative to predict the response to ICI, as well as identify the T cell receptor clonotypes present in brain metastasis., The study was undertaken with the support of the Fundación Asociación Española contra el Cáncer (AECC), FERO (EDM), Ramón Areces Foundation, Cellex Foundation, BBVA (CAIMI), the ISCIII, FIS (PI16/01278), the Ministerio de Ciencia, Innovación y Universidades (SAF2017-89109-P; AEI/FEDER, UE), the Juan de la Cierva formación fellowship (C.R.-P. and L.E.), Sara Borrell fellowship (E.P-R.). We acknowledge support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Program/Generalitat de Catalunya. We also acknowledge the support of the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III, the Generalitat de Catalunya through Departament de Salut and Departament d’Empresa i Coneixement, and the Co-financing by the Spanish Ministry of Ministry of Science and Innovation with funds from the European Regional Development Fund (ERDF) corresponding to the 2014–2020 Smart Growth Operating Program.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition

  • Jiménez Bernal, Isabel
  • Carabia Juberó, Júlia
  • Bobillo Varela, Sabela
  • Palacio García, Carlos
  • Abrisqueta, Pau
  • Nieto Sáchica, Juan Camilo
  • Castellví Vives, Josep
  • Martínez Ricarte, Francisco Ramón
  • Boix, Joan
  • Purroy Zuriguel, Noelia
  • Puigdefabregas Horta, Lluis
  • Seoane Suarez, Joan
  • Crespo Maull, Marta
  • Pagès Geli, Carlota
  • Bosch, Francesc
XPO1; BTK; Sistema immunitari innat, XPO1; BTK; Sistema inmune innato, XPO1; BTK; Innate immune system, Background Patients diagnosed with primary central nervous system lymphoma (PCNSL) often face dismal outcomes due to the limited availability of therapeutic options. PCNSL cells frequently have deregulated B-cell receptor (BCR) signaling, but clinical responses to its inhibition using ibrutinib have been brief. In this regard, blocking nuclear export by using selinexor, which covalently binds to XPO1, can also inhibit BCR signaling. Selinexor crosses the blood–brain barrier and was recently shown to have clinical activity in a patient with refractory diffuse large B-cell lymphoma in the CNS. We studied selinexor alone or in combination with ibrutinib in pre-clinical mouse models of PCNSL. Methods Orthotopic xenograft models were established by injecting lymphoma cells into the brain parenchyma of athymic mice. Tumor growth was monitored by bioluminescence. Malignant cells and macrophages were studied by immunohistochemistry and flow cytometry. Results Selinexor blocked tumor growth and prolonged survival in a bioluminescent mouse model, while its combination with ibrutinib further increased survival. CNS lymphoma in mice was infiltrated by tumor-promoting M2-like macrophages expressing PD-1 and SIRPα. Interestingly, treatment with selinexor and ibrutinib favored an anti-tumoral immune response by shifting polarization toward inflammatory M1-like and diminishing PD-1 and SIRPα expression in the remaining tumor-promoting M2-like macrophages. Conclusions These data highlight the pathogenic role of the innate immune microenvironment in PCNSL and provide pre-clinical evidence for the development of selinexor and ibrutinib as a new promising therapeutic option with cytotoxic and immunomodulatory potential., This work was supported by research funding from the Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias (PI17/00950, M.C., PI17/00943, F.B, PI18/01392, P.A., PI16/01278, J.S) cofinanced by the European Regional Development Fund (ERDF); Fundación Asociación Española Contra el Cáncer (M.C. and P.A.) and Gilead Fellowships (GLD16/00144, GLD18/00047, F.B). M.C. holds a contract from Ministerio de Ciencia, Innovación y Universidades (RYC-2012-12018). S.B. is the recipient of a postdoctoral fellowship from Fundación Alfonso Martin Escudero.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma

  • Escudero Monreal, Laura
  • Llort Sales, Anna
  • Arias Piñeiro, Alexandra
  • Diaz-Navarro, Ander
  • Martínez Ricarte, Francisco Ramón
  • Rubio Pérez, Carlota
  • Mayor Ferreras, Regina Gabriela
  • Caratú, Ginevra
  • Martinez Saez, Elena Antima
  • Vázquez Méndez, Josefa Élida
  • Hladun Alvaro, Raquel
  • Gros Subias, Luís
  • Ramon y Cajal Agüeras, Santiago
  • Poca Pastor, Ma Antonia
  • Sahuquillo Barris, Joan
  • Gallego Melcón, Soledad
  • Seoane Suarez, Joan
Genètica del càncer; Càncer del SNC; Càncer pediàtric, Genética del cáncer; Cáncer del SNC; Cáncer pediátrico, Cancer genetics; CNS cancer; Paediatric cancer, The molecular characterisation of medulloblastoma, the most common paediatric brain tumour, is crucial for the correct management and treatment of this heterogenous disease. However, insufficient tissue sample, the presence of tumour heterogeneity, or disseminated disease can challenge its diagnosis and monitoring. Here, we report that the cerebrospinal fluid (CSF) circulating tumour DNA (ctDNA) recapitulates the genomic alterations of the tumour and facilitates subgrouping and risk stratification, providing valuable information about diagnosis and prognosis. CSF ctDNA also characterises the intra-tumour genomic heterogeneity identifying small subclones. ctDNA is abundant in the CSF but barely present in plasma and longitudinal analysis of CSF ctDNA allows the study of minimal residual disease, genomic evolution and the characterisation of tumours at recurrence. Ultimately, CSF ctDNA analysis could facilitate the clinical management of medulloblastoma patients and help the design of tailored therapeutic strategies, increasing treatment efficacy while reducing excessive treatment to prevent long-term secondary effects., We would like to thank the patients at the Vall d’Hebron Hospital that were enrolled in the study and their families. The study was undertaken with the support of the Fundación Asociación Española contra el Cáncer (AECC), FERO (EDM), Ramón Areces Foundation, Cellex Foundation, BBVA (CAIMI), the ISCIII, FIS (PI16/01278) and the Juan de la Cierva fellowship (L.E). X.S.P. is supported by Ministerio de Economía y Competitividad (MINECO) SAF2013-45836-R and CIBERONC; A.D.N. is supported by the Department of Education of the Basque Government (grant number PRE_2017_1_0100). We thank CERCA Programme/Generalitat de Catalunya for institutional support.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program

  • Janin, Maxime
  • Ortiz‑Barahona, Vanessa
  • Castro de Moura, Manuel
  • Martínez‑Cardús, Anna
  • Llinàs‑Arias, Pere
  • Soler, Marta
  • Arias Piñeiro, Alexandra
  • Cuartas Maza, Ma Isabel
  • Seoane Suarez, Joan
Resultado clínico; Epitranscriptómica; Glioma, Clinical outcome; Epitranscriptomics; Glioma, Resultat clínic; Epitranscriptòmica; Glioma, Tumors have aberrant proteomes that often do not match their corresponding transcriptome profiles. One possible cause of this discrepancy is the existence of aberrant RNA modification landscapes in the so-called epitranscriptome. Here, we report that human glioma cells undergo DNA methylation-associated epigenetic silencing of NSUN5, a candidate RNA methyltransferase for 5-methylcytosine. In this setting, NSUN5 exhibits tumor-suppressor characteristics in vivo glioma models. We also found that NSUN5 loss generates an unmethylated status at the C3782 position of 28S rRNA that drives an overall depletion of protein synthesis, and leads to the emergence of an adaptive translational program for survival under conditions of cellular stress. Interestingly, NSUN5 epigenetic inactivation also renders these gliomas sensitive to bioactivatable substrates of the stress-related enzyme NQO1. Most importantly, NSUN5 epigenetic inactivation is a hallmark of glioma patients with long-term survival for this otherwise devastating disease., This work was supported by a European Research Council (ERC) Advanced Grant under the European Community’s Seventh Framework Program (FP7/2007-2013)/ERC Grant Agreement No. 268626—EPINORC project (to M. Esteller), the Ministerio de Economía y Competitividad (MINECO) under Grant No. SAF2014-55000-R (to M. Esteller) and the Instituto de Salud Carlos III (ISCIII), under the FIS PI16/01278 Project (to J. Seoane), the Integrated Project of Excellence no. PIE13/00022 (ONCOPROFILE) (to M. Esteller), CIBER 2016 CB16/12/00312 (CIBERONC) (to M. Esteller), co-financed by the European Development Regional Fund, ‘A way to achieve Europe’ ERDF, the AGAUR—Catalan Government (Project No. 2009SGR1315 and 2014SGR633) (to M. Esteller), the Cellex Foundation (to M. Esteller), Obra Social “La Caixa” (to M. Esteller), the CERCA Program and the Health and Science Departments of the Catalan Government (Generalitat de Catalunya) (to M. Esteller) and a grant from the National Health and Medical Research Council of Australia (APP1061551, to TP). M.W. Boudreau is a member of the NIH Chemistry-Biology Interface Training Program (T32-GM070421).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program

  • Janin, Maxime|||0000-0003-1013-4128
  • Ortiz-Barahona, V.
  • de Moura, M. C.
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Llinàs-Arias, Pere|||0000-0002-3666-0532
  • Soler, Marta|||0000-0002-6656-957X
  • Nachmani, D.
  • Pelletier, Joffrey|||0000-0001-9174-044X
  • Schumann, U.
  • Calleja-Cervantes, María Eréndira|||0000-0003-0688-0793
  • Moran, S.|||0000-0003-4192-8983
  • Guil, Sonia|||0000-0002-2257-3331
  • Bueno-Costa, Alberto|||0000-0001-8700-2540
  • Piñeyro, David|||0000-0001-5633-3339
  • Perez-Salvia, Montserrat
  • Rosselló-Tortella, M.
  • Piqué, Laia
  • Bech-Serra, Joan-Josep|||0000-0003-3486-781X
  • De La Torre Gómez, Gisela Carolina|||0000-0001-9363-291X
  • Vidal, August|||0000-0001-5727-2099
  • Martínez-Iniesta, M.
  • Martín-Tejera, J. F.
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Arias, Alexandra
  • Cuartas, Isabel
  • Aransay, Ana M.|||0000-0002-8271-612X
  • La Madrid, A. M.
  • Carcaboso, Angel M.|||0000-0002-8485-426X
  • Santa-Maria, V.
  • Mora, J.
  • Fernández, Agustín F.|||0000-0002-3792-4085
  • Fraga, M. F.
  • Aldecoa, Iban|||0000-0001-5774-7453
  • Pedrosa, Leire|||0000-0002-1852-4975
  • Graus Ribas, Francesc|||0000-0002-8924-8322
  • Vidal, Noemí|||0000-0002-2852-6667
  • Martinez, Fina|||0000-0002-0940-1025
  • Tortosa, Avelina|||0000-0002-9080-2976
  • Carrato, Cristina|||0000-0002-1953-8287
  • Balañá, Carmen|||0000-0003-0771-0390
  • Boudreau, M. W.
  • Hergenrother, P. J.
  • Kötter, P.
  • Entian, K. D.
  • Hench, Jürgen
  • Frank, Stephan|||0000-0001-6165-0187
  • Mansouri, S.
  • Zadeh, G.
  • Dans, P. D.
  • Orozco López, Modesto|||0000-0002-8608-3278
  • Thomas, Gareth J.
  • Blanco, Sandra
  • Seoane Suárez, Joan|||0000-0002-6541-5974
  • Preiss, T.
  • Pandolfi, P. P.
  • Esteller, M.|||0000-0003-4490-6093
Tumors have aberrant proteomes that often do not match their corresponding transcriptome profiles. One possible cause of this discrepancy is the existence of aberrant RNA modification landscapes in the so-called epitranscriptome. Here, we report that human glioma cells undergo DNA methylation-associated epigenetic silencing of NSUN5, a candidate RNA methyltransferase for 5-methylcytosine. In this setting, NSUN5 exhibits tumor-suppressor characteristics in vivo glioma models. We also found that NSUN5 loss generates an unmethylated status at the C3782 position of 28S rRNA that drives an overall depletion of protein synthesis, and leads to the emergence of an adaptive translational program for survival under conditions of cellular stress. Interestingly, NSUN5 epigenetic inactivation also renders these gliomas sensitive to bioactivatable substrates of the stress-related enzyme NQO1. Most importantly, NSUN5 epigenetic inactivation is a hallmark of glioma patients with long-term survival for this otherwise devastating disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy

  • Pascual-García, Mónica|||0000-0002-9768-0641
  • Bonfill-Teixidor, Ester|||0000-0002-9260-448X
  • Planas-Rigol, Ester|||0000-0001-5948-2241
  • Rubio-Perez, Carlota|||0000-0002-1921-168X
  • Iurlaro, Raffaella|||0000-0003-1019-6679
  • Arias, Alexandra
  • Cuartas, Isabel
  • Sala-Hojman, Ada
  • Escudero, Laura|||0000-0001-7385-673X
  • Martinez-Ricarte, Fran|||0000-0003-4567-0828
  • Huber-Ruano, Isabel
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Pedrosa, Leire|||0000-0002-1852-4975
  • Marques, Carlota|||0000-0002-8308-5630
  • Braña, Irene|||0000-0002-1068-9601
  • Garralda, Elena|||0000-0002-4412-7842
  • Vieito, María|||0000-0001-7531-343X
  • Squatrito, Juan|||0000-0002-4593-3790
  • Pineda, Estela|||0000-0003-2128-747X
  • Graus Ribas, Francesc|||0000-0002-8924-8322
  • Espejo, Carmen|||0000-0001-9949-5901
  • Sahuquillo Barris, Juan|||0000-0003-0713-5875
  • Tabernero, Josep|||0000-0002-2495-8139
  • Seoane Suárez, Joan|||0000-0002-6541-5974
Cancer response to immunotherapy depends on the infiltration of CD8 T cells and the presence of tumor-associated macrophages within tumors. Still, little is known about the determinants of these factors. We show that LIF assumes a crucial role in the regulation of CD8 T cell tumor infiltration, while promoting the presence of protumoral tumor-associated macrophages. We observe that the blockade of LIF in tumors expressing high levels of LIF decreases CD206, CD163 and CCL2 and induces CXCL9 expression in tumor-associated macrophages. The blockade of LIF releases the epigenetic silencing of CXCL9 triggering CD8 T cell tumor infiltration. The combination of LIF neutralizing antibodies with the inhibition of the PD1 immune checkpoint promotes tumor regression, immunological memory and an increase in overall survival.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition

  • Jiménez, Isabel|||0000-0002-5144-861X
  • Carabia, Júlia
  • Bobillo, Sabela|||0000-0001-7381-680X
  • Palacio-García, Carles|||0000-0002-9085-3327
  • Abrisqueta, Pau|||0000-0001-9625-7422
  • Pagès Geli, Carlota|||0000-0001-9200-3943
  • Nieto Sáchica, Juan Camilo|||0000-0002-3400-1488
  • Castellvi, Josep|||0000-0001-5745-9996
  • Martinez-Ricarte, Fran|||0000-0003-4567-0828
  • Escoda, Lourdes|||0000-0003-3288-9716
  • Perla, Cristóbal
  • Céspedes Torrez, Dennis H.
  • Boix, Joan
  • Purroy i Zuriguel, Noèlia
  • Puigdefàbregas, Lluís
  • Seoane Suárez, Joan|||0000-0002-6541-5974
  • Bosch Albareda, Francesc|||0000-0001-9241-2886
  • Crespo, Marta|||0000-0002-7732-7808
Patients diagnosed with primary central nervous system lymphoma (PCNSL) often face dismal outcomes due to the limited availability of therapeutic options. PCNSL cells frequently have deregulated B-cell receptor (BCR) signaling, but clinical responses to its inhibition using ibrutinib have been brief. In this regard, blocking nuclear export by using selinexor, which covalently binds to XPO1, can also inhibit BCR signaling. Selinexor crosses the blood-brain barrier and was recently shown to have clinical activity in a patient with refractory diffuse large B-cell lymphoma in the CNS. We studied selinexor alone or in combination with ibrutinib in pre-clinical mouse models of PCNSL. Orthotopic xenograft models were established by injecting lymphoma cells into the brain parenchyma of athymic mice. Tumor growth was monitored by bioluminescence. Malignant cells and macrophages were studied by immunohistochemistry and flow cytometry. Selinexor blocked tumor growth and prolonged survival in a bioluminescent mouse model, while its combination with ibrutinib further increased survival. CNS lymphoma in mice was infiltrated by tumor-promoting M2-like macrophages expressing PD-1 and SIRPα. Interestingly, treatment with selinexor and ibrutinib favored an anti-tumoral immune response by shifting polarization toward inflammatory M1-like and diminishing PD-1 and SIRPα expression in the remaining tumor-promoting M2-like macrophages. These data highlight the pathogenic role of the innate immune microenvironment in PCNSL and provide pre-clinical evidence for the development of selinexor and ibrutinib as a new promising therapeutic option with cytotoxic and immunomodulatory potential. The online version of this article (10.1007/s11060-020-03580-y) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas

  • Bobillo, Sabela|||0000-0001-7381-680X
  • Crespo, Marta|||0000-0002-7732-7808
  • Escudero, Laura|||0000-0001-7385-673X
  • Mayor, Regina
  • Raheja, Priyanka
  • Carpio Segura, Cecilia del Carmen|||0000-0001-9346-0134
  • Rubio-Perez, Carlota|||0000-0002-1921-168X
  • Tazon-Vega, Barbara
  • Palacio-García, Carles|||0000-0002-9085-3327
  • Carabia, Júlia
  • Jimenez, Isabel
  • Nieto Sáchica, Juan Camilo|||0000-0002-3400-1488
  • Montoro Gómez, Maria Julia|||0000-0001-9532-7417
  • Martinez-Ricarte, Francisco
  • Castellvi, Josep|||0000-0001-5745-9996
  • Simó Perdigó, Marc|||0000-0002-3982-8759
  • Puigdefabregas, Lluis
  • Abrisqueta, Pau|||0000-0001-9625-7422
  • Bosch Albareda, Francesc|||0000-0001-9241-2886
  • Seoane Suárez, Joan|||0000-0002-6541-5974
The levels of cell free circulating tumor DNA (ctDNA) in plasma correlate with treatment response and outcome in systemic lymphomas. Notably, in brain tumors, the levels of ctDNA in the cerebrospinal fluid (CSF) are higher than in plasma. Nevertheless, their role in central nervous system (CNS) lymphomas remains elusive. We evaluated the CSF and plasma from 19 patients: 6 restricted CNS lymphomas, 1 systemic and CNS lymphoma, and 12 systemic lymphomas. We performed whole exome sequencing or targeted sequencing to identify somatic mutations of the primary tumor, then variant-specific droplet digital polymerase chain reaction was designed for each mutation. At time of enrollment, we found ctDNA in the CSF of all patients with restricted CNS lymphoma but not in patients with systemic lymphoma without CNS involvement. Conversely, plasma ctDNA was detected in only 2 out of 6 patients with restricted CNS lymphoma with lower variant allele frequencies than CSF ctDNA. Moreover, we detected CSF ctDNA in one patient with CNS lymphoma in complete remission and in one patient with systemic lymphoma, 3 and 8 months before CNS relapse was confirmed, indicating that CSF ctDNA might detect CNS relapse earlier than conventional methods. Finally, in two cases with CNS lymphoma, CSF ctDNA was still detected after treatment even though no tumoral cells were observed by flow cytometry (FC), indicating that CSF ctDNA detected residual disease better than FC. In conclusion, CSF ctDNA can detect CNS lesions better than plasma ctDNA and FC. In addition, CSF ctDNA predicted CNS relapse in CNS and systemic lymphomas.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment

  • Rubio-Perez, Carlota|||0000-0002-1921-168X
  • Planas-Rigol, Ester|||0000-0001-5948-2241
  • Trincado Alonso, Juan Luis, 1987-|||0000-0001-5363-3774
  • Bonfill-Teixidor, Ester|||0000-0002-9260-448X
  • Arias, Alexandra
  • Marchese, Domenica|||0000-0002-3036-4580
  • Moutinho, Catia|||0000-0003-3885-0847
  • Serna, Garazi|||0000-0003-2666-0982
  • Pedrosa, Leire|||0000-0002-1852-4975
  • Iurlaro, Raffaella|||0000-0003-1019-6679
  • Martinez-Ricarte, Fran|||0000-0003-4567-0828
  • Escudero, Laura|||0000-0001-7385-673X
  • Cordero Asanza, Esteban|||0000-0003-0464-3014
  • Cicuendez, Marta|||0000-0002-2603-9072
  • Ruiz, Sara
  • Parra, Genís
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Gonzalez, Josep
  • Pineda, Estela|||0000-0003-2128-747X
  • Sahuquillo Barris, Juan|||0000-0003-0713-5875
  • Tabernero, Josep|||0000-0002-2495-8139
  • Heyn, Holger|||0000-0002-3276-1889
  • Seoane Suárez, Joan|||0000-0002-6541-5974
Brain metastases are the most common tumor of the brain with a dismal prognosis. A fraction of patients with brain metastasis benefit from treatment with immune checkpoint inhibitors (ICI) and the degree and phenotype of the immune cell infiltration has been used to predict response to ICI. However, the anatomical location of brain lesions limits access to tumor material to characterize the immune phenotype. Here, we characterize immune cells present in brain lesions and matched cerebrospinal fluid (CSF) using single-cell RNA sequencing combined with T cell receptor genotyping. Tumor immune infiltration and specifically CD8 + T cell infiltration can be discerned through the analysis of the CSF. Consistently, identical T cell receptor clonotypes are detected in brain lesions and CSF, confirming cell exchange between these compartments. The analysis of immune cells of the CSF can provide a non-invasive alternative to predict the response to ICI, as well as identify the T cell receptor clonotypes present in brain metastasis. The use of CSF for diagnosis of metastatic brain tumors could be of clinical and patient benefit. Here the authors undertake a single-cell RNA analysis of CSF and brain to determine whether the phenotype in the CSF is reflective of the phenotype in the tumor
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A single-cell tumor immune atlas for precision oncology

  • Nieto, Paula
  • Elosua-Bayes, Marc|||0000-0001-5315-815X
  • Trincado Alonso, Juan Luis, 1987-|||0000-0001-5363-3774
  • Marchese, Domenica|||0000-0002-3036-4580
  • Massoni-Badosa, Ramon
  • Salvany, Maria|||0000-0002-8573-4032
  • Henriques, Ana|||0000-0002-2421-4308
  • Nieto Sáchica, Juan Camilo|||0000-0002-3400-1488
  • Aguilar-Fernández, Sergio|||0000-0002-8869-1066
  • Mereu, Elisabetta|||0000-0001-6101-8472
  • Moutinho, Catia|||0000-0003-3885-0847
  • Ruiz, Sara
  • Lorden, Patricia
  • Chin, Vanessa T.
  • Kaczorowski, Dominik|||0000-0002-9205-1934
  • Chan, Chia Ling
  • Gallagher, Richard
  • Chou, Angela|||0000-0003-3925-7295
  • Planas-Rigol, Ester|||0000-0001-5948-2241
  • Rubio-Perez, Carlota|||0000-0002-1921-168X
  • Gut, Ivo|||0000-0001-7219-632X
  • Piulats, Josep M.|||0000-0002-3606-1724
  • Seoane Suárez, Joan|||0000-0002-6541-5974
  • Powell, Joseph E.|||0000-0002-5070-4124
  • Batlle, Eduard|||0000-0003-2422-0326
  • Heyn, Holger|||0000-0002-3276-1889
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma

  • Escudero Monreal, Laura
  • Llort Sales, Anna
  • Arias Piñeiro, Alexandra
  • Diaz-Navarro, Ander
  • Martínez Ricarte, Francisco Ramón
  • Rubio Pérez, Carlota
  • Mayor Ferreras, Regina Gabriela
  • Caratú, Ginevra
  • Martinez Saez, Elena Antima
  • Vázquez Méndez, Josefa Élida
  • Hladun Alvaro, Raquel
  • Gros Subias, Luís
  • Ramon y Cajal Agüeras, Santiago
  • Poca Pastor, Ma Antonia
  • Sahuquillo Barris, Joan
  • Gallego Melcón, Soledad
  • Seoane Suarez, Joan
Genètica del càncer; Càncer del SNC; Càncer pediàtric, Genética del cáncer; Cáncer del SNC; Cáncer pediátrico, Cancer genetics; CNS cancer; Paediatric cancer, The molecular characterisation of medulloblastoma, the most common paediatric brain tumour, is crucial for the correct management and treatment of this heterogenous disease. However, insufficient tissue sample, the presence of tumour heterogeneity, or disseminated disease can challenge its diagnosis and monitoring. Here, we report that the cerebrospinal fluid (CSF) circulating tumour DNA (ctDNA) recapitulates the genomic alterations of the tumour and facilitates subgrouping and risk stratification, providing valuable information about diagnosis and prognosis. CSF ctDNA also characterises the intra-tumour genomic heterogeneity identifying small subclones. ctDNA is abundant in the CSF but barely present in plasma and longitudinal analysis of CSF ctDNA allows the study of minimal residual disease, genomic evolution and the characterisation of tumours at recurrence. Ultimately, CSF ctDNA analysis could facilitate the clinical management of medulloblastoma patients and help the design of tailored therapeutic strategies, increasing treatment efficacy while reducing excessive treatment to prevent long-term secondary effects., We would like to thank the patients at the Vall d’Hebron Hospital that were enrolled in the study and their families. The study was undertaken with the support of the Fundación Asociación Española contra el Cáncer (AECC), FERO (EDM), Ramón Areces Foundation, Cellex Foundation, BBVA (CAIMI), the ISCIII, FIS (PI16/01278) and the Juan de la Cierva fellowship (L.E). X.S.P. is supported by Ministerio de Economía y Competitividad (MINECO) SAF2013-45836-R and CIBERONC; A.D.N. is supported by the Department of Education of the Basque Government (grant number PRE_2017_1_0100). We thank CERCA Programme/Generalitat de Catalunya for institutional support.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment

  • Rubio Pérez, Carlota
  • Planas Rigol, Ester
  • Trincado, Juan L.
  • Bonfill Teixidor, Ester
  • Arias Piñeiro, Alexandra
  • Marchese, Domenica
  • Iurlaro, Raffaella
  • Martínez Ricarte, Francisco Ramón
  • Escudero Monreal, Laura
  • Cordero Asanza, Esteban Xavier
  • Cicuendez López Ocaña, Marta
  • Nuciforo, Paolo Giovanni
  • Sahuquillo Barris, Joan
  • Tabernero, Josep
  • Seoane Suarez, Joan
  • Serna, Garazi
Microambient del càncer; Immunologia tumoral, Microambiente del cáncer; Inmunología tumoral, Cancer microenvironment; Tumour immunology, Brain metastases are the most common tumor of the brain with a dismal prognosis. A fraction of patients with brain metastasis benefit from treatment with immune checkpoint inhibitors (ICI) and the degree and phenotype of the immune cell infiltration has been used to predict response to ICI. However, the anatomical location of brain lesions limits access to tumor material to characterize the immune phenotype. Here, we characterize immune cells present in brain lesions and matched cerebrospinal fluid (CSF) using single-cell RNA sequencing combined with T cell receptor genotyping. Tumor immune infiltration and specifically CD8+ T cell infiltration can be discerned through the analysis of the CSF. Consistently, identical T cell receptor clonotypes are detected in brain lesions and CSF, confirming cell exchange between these compartments. The analysis of immune cells of the CSF can provide a non-invasive alternative to predict the response to ICI, as well as identify the T cell receptor clonotypes present in brain metastasis., The study was undertaken with the support of the Fundación Asociación Española contra el Cáncer (AECC), FERO (EDM), Ramón Areces Foundation, Cellex Foundation, BBVA (CAIMI), the ISCIII, FIS (PI16/01278), the Ministerio de Ciencia, Innovación y Universidades (SAF2017-89109-P; AEI/FEDER, UE), the Juan de la Cierva formación fellowship (C.R.-P. and L.E.), Sara Borrell fellowship (E.P-R.). We acknowledge support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Program/Generalitat de Catalunya. We also acknowledge the support of the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III, the Generalitat de Catalunya through Departament de Salut and Departament d’Empresa i Coneixement, and the Co-financing by the Spanish Ministry of Ministry of Science and Innovation with funds from the European Regional Development Fund (ERDF) corresponding to the 2014–2020 Smart Growth Operating Program.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program

  • Janin, Maxime
  • Ortiz‑Barahona, Vanessa
  • Castro de Moura, Manuel
  • Martínez‑Cardús, Anna
  • Llinàs‑Arias, Pere
  • Soler, Marta
  • Arias Piñeiro, Alexandra
  • Cuartas Maza, Ma Isabel
  • Seoane Suarez, Joan
Resultado clínico; Epitranscriptómica; Glioma, Clinical outcome; Epitranscriptomics; Glioma, Resultat clínic; Epitranscriptòmica; Glioma, Tumors have aberrant proteomes that often do not match their corresponding transcriptome profiles. One possible cause of this discrepancy is the existence of aberrant RNA modification landscapes in the so-called epitranscriptome. Here, we report that human glioma cells undergo DNA methylation-associated epigenetic silencing of NSUN5, a candidate RNA methyltransferase for 5-methylcytosine. In this setting, NSUN5 exhibits tumor-suppressor characteristics in vivo glioma models. We also found that NSUN5 loss generates an unmethylated status at the C3782 position of 28S rRNA that drives an overall depletion of protein synthesis, and leads to the emergence of an adaptive translational program for survival under conditions of cellular stress. Interestingly, NSUN5 epigenetic inactivation also renders these gliomas sensitive to bioactivatable substrates of the stress-related enzyme NQO1. Most importantly, NSUN5 epigenetic inactivation is a hallmark of glioma patients with long-term survival for this otherwise devastating disease., This work was supported by a European Research Council (ERC) Advanced Grant under the European Community’s Seventh Framework Program (FP7/2007-2013)/ERC Grant Agreement No. 268626—EPINORC project (to M. Esteller), the Ministerio de Economía y Competitividad (MINECO) under Grant No. SAF2014-55000-R (to M. Esteller) and the Instituto de Salud Carlos III (ISCIII), under the FIS PI16/01278 Project (to J. Seoane), the Integrated Project of Excellence no. PIE13/00022 (ONCOPROFILE) (to M. Esteller), CIBER 2016 CB16/12/00312 (CIBERONC) (to M. Esteller), co-financed by the European Development Regional Fund, ‘A way to achieve Europe’ ERDF, the AGAUR—Catalan Government (Project No. 2009SGR1315 and 2014SGR633) (to M. Esteller), the Cellex Foundation (to M. Esteller), Obra Social “La Caixa” (to M. Esteller), the CERCA Program and the Health and Science Departments of the Catalan Government (Generalitat de Catalunya) (to M. Esteller) and a grant from the National Health and Medical Research Council of Australia (APP1061551, to TP). M.W. Boudreau is a member of the NIH Chemistry-Biology Interface Training Program (T32-GM070421).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition

  • Jiménez Bernal, Isabel
  • Carabia Juberó, Júlia
  • Bobillo Varela, Sabela
  • Palacio García, Carlos
  • Abrisqueta, Pau
  • Nieto Sáchica, Juan Camilo
  • Castellví Vives, Josep
  • Martínez Ricarte, Francisco Ramón
  • Boix, Joan
  • Purroy Zuriguel, Noelia
  • Puigdefabregas Horta, Lluis
  • Seoane Suarez, Joan
  • Crespo Maull, Marta
  • Pagès Geli, Carlota
  • Bosch, Francesc
XPO1; BTK; Sistema immunitari innat, XPO1; BTK; Sistema inmune innato, XPO1; BTK; Innate immune system, Background Patients diagnosed with primary central nervous system lymphoma (PCNSL) often face dismal outcomes due to the limited availability of therapeutic options. PCNSL cells frequently have deregulated B-cell receptor (BCR) signaling, but clinical responses to its inhibition using ibrutinib have been brief. In this regard, blocking nuclear export by using selinexor, which covalently binds to XPO1, can also inhibit BCR signaling. Selinexor crosses the blood–brain barrier and was recently shown to have clinical activity in a patient with refractory diffuse large B-cell lymphoma in the CNS. We studied selinexor alone or in combination with ibrutinib in pre-clinical mouse models of PCNSL. Methods Orthotopic xenograft models were established by injecting lymphoma cells into the brain parenchyma of athymic mice. Tumor growth was monitored by bioluminescence. Malignant cells and macrophages were studied by immunohistochemistry and flow cytometry. Results Selinexor blocked tumor growth and prolonged survival in a bioluminescent mouse model, while its combination with ibrutinib further increased survival. CNS lymphoma in mice was infiltrated by tumor-promoting M2-like macrophages expressing PD-1 and SIRPα. Interestingly, treatment with selinexor and ibrutinib favored an anti-tumoral immune response by shifting polarization toward inflammatory M1-like and diminishing PD-1 and SIRPα expression in the remaining tumor-promoting M2-like macrophages. Conclusions These data highlight the pathogenic role of the innate immune microenvironment in PCNSL and provide pre-clinical evidence for the development of selinexor and ibrutinib as a new promising therapeutic option with cytotoxic and immunomodulatory potential., This work was supported by research funding from the Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias (PI17/00950, M.C., PI17/00943, F.B, PI18/01392, P.A., PI16/01278, J.S) cofinanced by the European Regional Development Fund (ERDF); Fundación Asociación Española Contra el Cáncer (M.C. and P.A.) and Gilead Fellowships (GLD16/00144, GLD18/00047, F.B). M.C. holds a contract from Ministerio de Ciencia, Innovación y Universidades (RYC-2012-12018). S.B. is the recipient of a postdoctoral fellowship from Fundación Alfonso Martin Escudero.